Our Team

Management Team

Winston Z. Ho, Ph.D.

Founder, President & CTO
Founder and CEO Maxwell Sensors, Inc., Director of Sensor Systems at Intelligent Optical Systems, Inc., Director of Biomedical Optics at Physical Optics Corp. 52 published papers and 15 issued patents. Winston Ho served as an SPIE program committee and NIH grant review committee. MS Biochemistry and Ph.D. Biophysics from Arizona State University, and then worked as a postdoctoral fellow at Columbia University in New York and a Research Scientist at University of Arizona (Optical Science Center).


Michael Aye, Ph.D.

Vice President of Molecular Products
Prior to joining Applied BioCode, Dr. Aye was the Technical Director, Assay Development at Focus Diagnostics (subsidiary of Quest Diagnostics). He developed and commercialized IVD products, including SimplexaTM Mycoplasma pneumoniae assay, Influenza A H1N1, and Flu A/B & RSV assay, as well as Simplexa Direct chemistry and Sample-to-Answer molecular detection system. He has developed and launched over 40 molecular products, including ASR, GPR, RUO, CE IVD and FDA 510(k) cleared products. Dr. Aye obtained his doctoral degree in Biology from the University of California, Irvine.


Andy Chao

Controller
Andy Chao has served start-up to fortune 100 Companies as an auditor, consultant, and management role. He has extensive healthcare experience with an accredited hospital holding company, medical device manufacture, pharmaceutical, and diagnostic companies. He co-leads SEC S-1 audit and filing with Big Five accounting firm. He drafts accounting pronouncements under US GAAP and IFRS for multi-billion dollar consumer products, diagnostic, and technology clients. Consulting financial controls and reviews for medical device manufacture and pharmaceutical, he has helped the clients streamline the process and save $1.2 million and $3 million, respectively. As a management for the accredited hospital and consumer product companies, he manages quarterly SEC reporting, internal controls, financial planning, and periodic financial audits.


Michael Ho, Ph.D.

Director of Technical Services
Michael Ho, Ph.D. joined Applied BioCode, Inc. in 2015 as Director of Technical Services that leads and directs the Technical Services group for Applied BioCode products globally. Michael has extensive knowledge in molecular diagnostic products for clinical, foodborne, veterinary, and biodefense applications. He excelled in development and support of PCR based chemistry and instrument platforms since 1996. He also specialized in nucleic acid extraction methodology and received a patent on the subject. He majored in Medical Microbiology & Immunology at San Jose State University, California, and received his Ph.D. in Microbiology from University of California at Davis. Prior to joining Applied BioCode, Michael led Technical Service and Product Development operations at Applied Biosystems (Thermo Fisher), Cepheid, EraGen Biosciences, Luminex, and Focus Diagnostics (Quest Diagnostics).


Jerry Kowalski

Director of Software and Compliance
As Director of Software and Compliance, Mr. Kowalski is responsible for directing software development for products requiring FDA clearance. Prior to Joining Applied BioCode, Mr. Kowalski was Director of Software Engineering at Applied Medical where he was instrumental in completing UL, CE, and FDA submissions and obtaining clearance. As Software Manager at Beckman Coulter he led product development and commercialization of multiple products at several California development sites. Major platforms included DNA Sequencing, Protein Analysis, and Centrifugation systems. With 15 years at Beckman Coulter, he served as a core program team member in the development, commercialization and support of multiple platforms serving life-science, biomedical and molecular diagnostic markets. Mr. Kowalski earned his degree in Electrical Engineering Technology from Michigan Technological University.


Steven Partono, Ph.D.

Director of Quality Assurance
Steve is responsible for managing the continued development, implementation and maintenance of quality systems and activities within an FDA and ISO 13485 regulated medical device environment, and facilitating interdepartmental cooperation required to achieve corporate objectives. Prior to joining Applied BioCode, he worked at Teco Diagnostics where he was responsible for quality assurance and regulatory affairs for IVD products. He also spent time at Nesher Technologies where he was a co-inventor of a patented method for multiplexed and ultrasensitive microRNA detection using alternating laser excitation technology. He was also involved in academic research at the Scripps Research Institute and the University of Florida. He received his doctoral degree in Biochemistry from Indiana University.


Winston Town, Ph.D.

Chief Executive Officer, Applied BioCode Taiwan Ltd.
Dr. Winston Town, Ph.D. served as Chairman of the Board and President of Fountain Biopharma Inc from March 2013 to December 24, 2015. Dr. Town served as the Chief Executive Officer of Panacor Bioscience Limited. He served as Senior Vice President of GloboAsia LLC, which provides scientific assistance to applicants seeking regulatory approval for drug development. He has spearheaded seven successful investigational new drug filings with the US Food and Drug Administration and has been consulted on more than ten drug development processes. Dr. Town has an extensive network within Asia and Greater China in sales and marketing. Prior to GloboAsia LLC, he was with ConAgra International of the US and Hofflinghouse UK, where he was responsible for the development of the marketing and distribution network.


Donald Wong

Vice President of Productions
Experienced manufacturing and operations manager in the in vitro diagnostics and pharmaceutical industries. Director of Manufacturing ProteoGenix, Inc., Director of Manufacturing and QC BioCentrex, LLC, Director of QC and Calibration CareSide, Inc., Manager R&D SmithKline Beecham Clinical Laboratories. BA in Biology and Six Sigma Black Belt certificate from UCLA.


Consulting Team

Robert Di Tullio

Regulatory, Quality and Clinical Affairs
Mr. Robert Di Tullio has 40 years of experience in the in vitro diagnostics industry, the last 28 of which is in regulatory, clinical and quality management. Previously, he was Vice President, Global Regulatory and Clinical Affairs for Alere and held similar positions at ProteoGenix, Sequenom, Siemens Medical Solutions Diagnostics and Diagnostic Products Corporation. Robert is currently the industry liaison to the Clinical Laboratory Improvement Advisory Committee (CLIAC) and a long-time member of the Regulatory Affairs Professionals Society (RAPS). Robert was the co-chair of the AdvaMed Diagnostics Task Force from 2007 to 2013, and was an advisory board member for the Medical Device graduate degree curriculum at the University of Southern California. He received a B.S. in Biology from Saint Joseph's University in Philadelphia.


Don Mooney

Business Relations & Commercialization
Mr. Mooney has served as an executive in a variety of Fortune 500 healthcare companies including Johnson & Johnson and Bausch and Lomb. As a Division level President, he has extensive worldwide executive sales, marketing and commercial operations experience in the Medical Products and Diagnostics industry. Don has an extraordinary track record in full line functional responsibility, strategy innovation, integrating organizations, identifying and negotiating business alliances, and changing organization culture to meet changing market dynamics.


Robert Wessel

Marketing & Strategic Planning
Mr. Wessel has over 30 years of global experience in the Clinical In-vitro Diagnostics markets. He was the Vice President of Sales, Marketing and Corporate Development for BioCentrix (Culver City, CA) as well as Director, Global Strategic Marketing and Planning for Beckman Coulter Inc. (Brea, CA). During his 25 years at Beckman Coulter, Bob was responsible for strategic planning, strategic marketing, product management, and new product commercialization for Beckman Coulter's Clinical Diagnostic Division. Mr. Wessel received a Bachelor's Degree in Bacteriology from UCLA.


Advisory Team

Stephen Sun Chiao, Ph.D.

Sycamore Ventures, Managing Partner
Dr. Chiao is a Managing Partner of Sycamore Ventures in charge of technology investment. Since 2002, he has served on the investment committee for both SVC and AsiaStar investment funds. Over the last 15 years, he has served on the Board of Directors for many companies. Prior to joining Sycamore, Dr. Chiao held various senior management & technical positions at Gould/AMI, Hewlett-Packard and Varian Associates. He also advised several high-tech startups and investments in Silicon Valley. Dr. Chiao serves on the boards of ACM, Corrigo and TeleNav. He also serves as a senior advisor to AOI, Aplus Flash, illuminate, and Solargiga Energy.


Romney M. Humphries, Ph.D.

UCLA, Clinical Microbiology
Romney M Humphries, Ph.D., D(ABMM), M (ASCP)CM, is the Section Chief of Clinical Microbiology at the UCLA Health System and an Assistant Professor, in the Department of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA. She completed her Doctor of Philosophy degree in Bacterial Pathogenesis studying the bacterial pathogenesis at the University of Calgary, Canada. She completed a clinical postdoctoral fellowship in Medical and Public Health Laboratory Microbiology at UCLA. She is a Diplomate of the American Board of Medical Microbiology and a licensed Clinical Microbiologist. Her research interests are in antimicrobial susceptibility testing and resistance mechanisms, Clostridium difficile infection, diagnostics and pathogenesis, and in the development of rapid molecular tests for the detection, quantification, and characterization of microorganisms in clinical specimens for the diagnosis of infectious diseases.


Professor Nouri Neamati, Ph.D.

USC, School of Pharmacology Pharmacy
Neamati's work primarily focuses on cancer and HIV. He currently has compounds at various stages of development - from theoretical to in vitro to in vivo. Some of these compounds have been shown to work in experimental mouse disease models while exhibiting no toxicity. Collaborating with colleagues at the Norris Cancer Center, Neamati aims to take these promising therapeutics into clinical trials. His research has also developed compounds for diabetes, and through collaboration, has discovered a drug for muscular dystrophy that is currently in the early stages of development. Dr. Neamati obtained a Ph.D. in biomedical sciences from the University of Texas Graduate School of Biomedical Sciences and M.D. Anderson Cancer Center, Houston, Texas. From 1995-2000, he was a postdoctoral fellow and a research fellow at the National Institutes of Health. In September 2000, he joined the University of Southern California School of Pharmacy with a joint appointment at the Norris Comprehensive Cancer Center.


Professor William J. Rutter, Ph.D.

UCSF, Chiron Founder
In 1981 Dr. Rutter and two colleagues founded Chiron in an effort to explore the business applications and potential solutions to problems of human disease. He conducted Hepatitis B research, which resulted in development with Chiron and Merck of the vaccine for Hepatitis B, the first recombinant vaccine. Also at Chiron, he worked on the first sequencing of the HIV genome, and discovered, sequenced, and cloned the Hepatitis C virus. This opened the way for the development of diagnostic tests, therapeutic drugs, and vaccines against these viruses, and pioneered other projects aimed at therapy of cancer and metabolic disease. He founded Synergenics, L.L.C., a consortium of commonly owned but independent biotech companies organized to offer a cost-effective approach to startups in the life sciences industry. In late 2007, UCSF announced that Mission Bay's newest building, designed to facilitate communications between industry and the campus, would be named the "William Rutter Center". Dr. William J. Rutter earned a B.S. in biochemistry from Harvard University, a M.S. from the University of Utah and his Ph.D. in biochemistry at the University of Illinois.


Cheri Walker, Ph.D.

SFW Capital Partners, Operating Executive
Dr. Walker is the Chief Commercial Officer at SeraCare Life Sciences. Previously Dr. Walker was Senior Vice President of Corporate Development at Charles River Labs (NYSE: CRL) a leading contract research organization. Prior to Charles River, Dr. Walker was Vice President, Mergers and Acquisitions for Qiagen N.V (NASDAQ: QGEN), a leader in life science tools and molecular diagnostics. She was also previously a Vice President of the Proteomics Business Segment and Vice President of corporate development for Life Technologies (NASDAQ: LIFE) and a Vice President in the equity research group at Deutsche Bank covering Life Science Tools. Dr. Walker has a BA in Biology from Swarthmore College and a Ph.D. in Human and Molecular Genetics from Baylor College.


Professor Yun Yen, M.D., Ph.D.

City of Hope, Molecular Pharmacology
Dr. Yen is a Full Professor and Chair of the Department of Molecular Pharmacology and Staff Physician of Medical Oncology, and Director of the Molecular Pharmacology Department at the Beckman Research Institute of the City of Hope in Duarte, California. He leads the translational research at City of Hope. The translation work focuses on early marker detection, genome medicine, and targeted therapy. He serves several positions at City of Hope which include Associate Director for Translational Research, Comprehensive Cancer Center; Dr. & Mrs. Allen Y. Chao Chair in Developmental Cancer Therapeutics, Endowed Chair; Co-leader, Developmental Cancer Therapeutics Program, Comprehensive Cancer Center; Professor and Chair, Molecular Pharmacology; and Interim Chair, Medical Oncology & Therapeutics Research. Dr Yen obtained his Ph.D. from Thomas Jefferson University, Philadelphia, PA, Pathology & Cell Biology, and his M.D. from Taipei Medical College, Taipei, Taiwan.


Stephen Young, Ph.D., D(ABMM)

TriCore Reference Laboratories and University of New Mexico
Stephen Young, Ph.D., received his B.S. and M.S. in Biological Sciences from Wright State University and his Ph.D. from the University of New Mexico. He completed an American Board of Medical Microbiology (ABMM) post-doctoral fellowship program at the University of Washington. Dr. Young has been a Diplomat of the American Board of Medical Microbiology for last 21 years. Dr. Young rose through the academic ranks at the University of New Mexico achieving the rank of Professor in the Department of Pathology. His primary responsibility in his academic appointment at UNM was to be the Director of Clinical Virology and with the formation of TriCore Reference Laboratories, in 1998, he assumed the responsibilities for both Microbiology and Virology. Dr. Young served as the Director of the Infectious Disease Section for 17 years. Along with his service responsibilities was funded for ten years by Sandia National Laboratories working on the development of long range sensors for biodefense. Dr. Young has been a collaborator for 25 years in the Multi-Center AIDS Cohort Study is active on several NIH grants affiliated with this cohort. Dr. Young’s has active research in evaluation and development of diagnostic products for clinical microbiology and has completed approximately 100 FDA in vitro diagnostic device trials or market evaluations of diagnostic tests. Recently, Dr. Young retired from the University of New Mexico, but remains as faculty as Professor Emeritus in the Department of Pathology to continue a research contract. Dr. Young is now in a new role as Director of Research and Clinical Trials at TriCore Reference Laboratories.